Rituximab: Modes of action, remaining dispute and future perspective

Future Oncology

Volumn 10, Issue 15, 2014, Pages 2481-2492

  Abulayha, Abdulmunem ^a   Bredan, Amin ^b,c   El Enshasy, Hesham ^d   Daniels, Ian ^e  

^a Biotechnology Research Center   (Libyan Arab Jamahiriya)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITI TEKNOLOGI MALAYSIA   (Malaysia)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

apoptosis; caspases; cell death; mechanism; rituximab

Indexed keywords

RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG MECHANISM; HUMAN; IMMUNOSTIMULATION; REVIEW; TARGET CELL;

EID: 84920028469     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.146     Document Type: Review

References (96)

1. Schwaber J, Cohen EP. Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types. Nature 244(5416), 444-447 (1973).
2. Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics 2(4), 619-633 (2008).
3. Martin P, Furman RR, Coleman M et al. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clin. Cancer Res. 13(18 Pt 2), 5636s-5642s (2007).
4. Gurcan HM, Keskin DB, Stern JN et al. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 9(1), 10-25 (2009).
5. Kasi PM, Tawbi HA, Oddis CV et al. Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective. Crit. Care 16(4), 231 (2012).
6. Banchereau J, Rousset F. Human B lymphocytes: phenotype, proliferation, and differentiation. Adv. Immunol. 52, 125-262 (1992).
7. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2), 435-445 (1994).
8. Binder M, Otto F, Mertelsmann R et al. The epitope recognized by rituximab. Blood 108(6), 1975-1978 (2006).
9. Li H, Ayer LM, Lytton J et al. Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. 278(43), 42427-42434 (2003).
10. Uchida J, Lee Y, Hasegawa M et al. Mouse CD20 expression and function. Int. Immunol. 16(1), 119-129 (2004).
11. Tedder TF, Forsgren A, Boyd AW et al. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur. J. Immunol. 16(8), 881-887 (1986).
12. Tedder TF, Boyd AW, Freedman AS et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J. Immunol. 135(2), 973-979 (1985).
13. Clark EA, Shu G. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J. Immunol. 138(3), 720-725 (1987).
14. Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J. Immunol. 135(6), 3795-3801 (1985).
15. Bezombes C, Grazide S, Garret C et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104(4), 1166-1173 (2004).
16. O'Keefe TL, Williams GT, Davies SL et al. Mice carrying a CD20 gene disruption. Immunogenetics 48(2), 125-132 (1998).
17. Einfeld DA, Brown JP, Valentine MA et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7(3), 711-717 (1988).
18. Press OW, Howell-Clark J, Anderson S et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83(5), 1390-1397 (1994).
19. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8), 2457-2466 (1994).
20. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6), 2188-2195 (1997).
21. Cabanillas F, Liboy I, Pavia O et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann. Oncol. 17(9), 1424-1427 (2006).
22. van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. 72(9), 1496-1502 (2013).
23. Makatsori M, Kiani-Alikha S, Manson AL et al. Hypogammaglobulinaemia after rituximab treatment-its incidence and outcome. QJM 107(10), 821-828 (2014).
24. McLaughlin P, Grillo-Lopez AJ, Link, BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998).
25. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 30(2), 393-403 (2004).
26. Abulayha AM, Tabal SA, Shawesh EI et al. Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma. Leuk. Res. 34(3), 307-311 (2010).
27. Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum. 56(5), 1464-1477 (2007).
28. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56(9), 3044-3056 (2007).
29. Anderson DR, Grillo-Lopez A, Varns C et al. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25(2), 705-708 (1997).
30. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19(2), 239-245 (2007).
31. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 290(5489), 84-89 (2000).
32. Clynes RA, Towers TL, Presta LG et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6(4), 443-446 (2000).
33. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3), 754-758 (2002).
34. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21), 3940-3947 (2003).
35. Farag SS, Flinn IW, Modali R et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103(4), 1472-1474 (2004).
36. Suzuk M, Yamanoi A, Machino Y et al. Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcgammaRIIIA. Biochem. Biophys. Res. Commun. 436(3), 519-524 (2013).
37. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101(3), 949-954 (2003).
38. Gluck WL, Hurst D, Yuen A et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10(7), 2253-2264 (2004).
39. Ansell SM, Witzig TE, Kurtin PJ et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99(1), 67-74 (2002).
40. Cartron G, Zhao-Yang L, Baudard M et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J. Clin. Oncol. 26(16), 2725-2731 (2008).
41. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51(6), 634-641 (2000).
42. Kennedy AD, Beum PV, Solga MD et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172(5), 3280-3288 (2004).
43. van der Kolk LE, Grillo-Lopez AJ, Baars JW et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 115(4), 807-811 (2001).
44. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13(9), 954-966 (2008).
45. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30(6), 286-292 (2009).
46. Macor P, Tripodo C, Zorzet S et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 67(21), 10556-10563 (2007).
47. Ziller F, Macor P, Bulla R et al. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 35(7), 2175-2183 (2005).
48. Horl S, Banki Z, Huber G et al. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 27(11), 2200-2208 (2013).
49. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98(5), 1352-1357 (2001).
50. Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101(3), 1045-1052 (2003).
51. Vega MI, Huerta-Yepez S, Martinez-Paniagua M et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin. Cancer Res. 15(21), 6582-6594 (2009).
52. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin. Cancer Res. 7(3), 709-723 (2001).
53. Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99(3), 1038-1043 (2002).
54. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97(5), 1392-1398 (2001).
55. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26(2), 133-143 (2000).
56. Jazirehi AR, Huerta-Yepez S, Cheng G et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 65(1), 264-276 (2005).
57. Mathas S, Rickers A, Bommert K et al. Anti-CD20-and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 60(24), 7170-7176 (2000).
58. Pedersen IM, Buhl AM, Klausen P et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99(4), 1314-1319 (2002).
59. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48(12), 673-683 (2000).
60. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 26(42), 6184-6193 (2007).
61. Xu ZZ, Xia ZG, Wang AH et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann. Hematol. 92(10), 1351-1358 (2013).
62. Jazirehi AR, Vega MI, Chatterjee D et al. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res. 64(19), 7117-7126 (2004).
63. Kondo E, Yoshino T. Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: insight into B-cell lymphomagenesis. Pathol. Int. 57(7), 391-397 (2007).
64. Haynes AP, Daniels I, Abhulayha AM et al. CD95 (Fas) expression is regulated by sequestration in the Golgi complex in B-cell lymphoma. Br. J. Haematol. 118(2), 488-494 (2002).
65. Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin. Hematol. 47(2), 133-142 (2010).
66. Vogler M, Dinsdale D, Dyer MJ et al. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 16(3), 360-367 (2009).
67. van der Kolk LE, Evers LM, Omene C et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 16(9), 1735-1744 (2002).
68. Eeva J, Nuutinen U, Ropponen A et al. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells. Apoptosis 14(5), 687-698 (2009).
69. Sieber S, Gdynia G, Roth W et al. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. Int. J. Oncol. 35(1), 149-158 (2009).
70. Vega MI, Huerta-Yepez S, Jazirehi AR et al. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 24(55), 8114-8127 (2005).
71. Vega MI, Jazirehi AR, Huerta-Yepez S et al. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J. Immunol. 175(4), 2174-2183 (2005).
72. Stel AJ, Ten Cate B, Jacobs S et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J. Immunol. 178(4), 2287-2295 (2007).
73. Scaffidi C, Fulda S, Srinivasan A et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17(6), 1675-1687 (1998).
74. Li H, Zhu H, Xu CJ et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4), 491-501 (1998).
75. Chan HT, Hughes D, French RR et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 63(17), 5480-5489 (2003).
76. Daniels I, Abulayha AM, Thomson BJ et al. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 11(6), 1013-1023 (2006).
77. Turzanski J, Daniels I, Haynes AP. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br. J. Haematol. 145(1), 137-140 (2009).
78. Mathiasen IS, Jaattela M. Triggering caspase-independent cell death to combat cancer. Trends Mol. Med. 8(5), 212-220 (2002).
79. Besnault L, Schrantz N, Auffredou MT et al. B cell receptor cross-linking triggers a caspase-8-dependent apoptotic pathway that is independent of the death effector domain of Fas-associated death domain protein. J. Immunol. 167(2), 733-740 (2001).
80. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann. Hematol. 83(10), 634-645 (2004).
81. Daniels I, Turzanski J, Haynes AP. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br. J. Haematol. 142(3), 394-403 (2008).
82. Jak M, van Bochove GG, van Lier RA et al. CD40 stimulation sensitizes CLL cells to rituximab-induced cell death. Leukemia 25(6), 968-978 (2011).
83. Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin. Cancer Res. 8(3), 836-845 (2002).
84. Lee WK, Thevenod F. Novel roles for ceramides, calpains and caspases in kidney proximal tubule cell apoptosis: lessons from in vitro cadmium toxicity studies. Biochem. Pharmacol. 76(11), 1323-1332 (2008).
85. Johnson DE. Noncaspase proteases in apoptosis. Leukemia 14(9), 1695-1703 (2000).
86. Janas E, Priest R, Wilde JI et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. 139(3), 439-446 (2005).
87. Daniels I, Abulayha A, Haynes AP. Hydroxyurea potentiates the caspase-independent killing of B-cell lines by rituximab and GA101. Oncol. Res. 20(12), 545-555 (2013).
88. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract. Res. Clin. Haematol. 24(2), 203-216 (2011).
89. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6), 1793-1800 (2004).
90. Milani C, Castillo J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr. Opin. Mol. Ther. 11(2), 200-207 (2009).
91. Dalle S, Reslan L, Besseyre de Horts T et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol. Cancer Ther. 10(1), 178-185 (2011).
92. Lazar GA, Dang W, Karki S et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103(11), 4005-4010 (2006).
93. de Romeuf C, Dutertre CA, Le Garff-Tavernier M et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/ CD16. Br. J. Haematol. 140(6), 635-643 (2008).
94. Salles GA, Morschhauser F, Solal-Celigny P et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the Phase II GAUGUIN study. J. Clin. Oncol. 31(23), 2920-2926 (2013).
95. Cameron F, McCormack PL. Obinutuzumab: first global approval. Drugs 74(1), 147-154 (2014).
96. Dall'Ozzo S, Tartas S, Paintaud G et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64(13), 4664-4669 (2004).